Transforming Growth Factor ß1 and Gap Junction Protein Alpha 4 Gene Heterogeneity in Relation to the Severity of Clinical Disease in Cystic Fibrosis

• Published in: Frontiers in bioscience (Landmark. Print) 2023-07, Vol.28 (7), p.138-138
• Main Authors: Laubach, Joern Pascal, Ludwig, Michael, Horn, Tabea, Eickmeier, Olaf, Smaczny, Christina, Schubert, Ralf, Zielen, Stefan, Majoor, Christof, Aydin, Malik, Schnell, Alexander, Schmitt-Grohé, Sabina
• Format: Article
• Language: English
• Subjects: bronchial inflammation; cystic fibrosis; f508del homozygous; gap junction protein alpha 4; gene–gene interaction; geno-/phenotype relation; precision medicine; transforming growth factor beta1
• ISSN: 2768-6701; 2768-6698
• DOI: 10.31083/j.fbl2807138

High TGFβ1-producing variants cause severe clinical disease in F508del homozygous patients. Lately, we showed that a single nucleotide polymorphism (SNP), rs41266431, in the GJA4 gene modifies the disease severity of cystic fibrosis (CF). Our aim was to investigate whether the clinical phenotype associated with GJA4 variants was independent of TGFβ1 variants. Homozygous F508del patients (n = 115, mean age 27.2 years, m/f (65/50)) were included in this study. A deep sequence analysis was performed for GJA4 and TGBβ1, and disease severity was assessed over 3 years using lung function tests (LFTs), body mass index, diabetes mellitus, colonization with survival to end-stage lung disease (ESLD), as well as distinct inflammatory biomarkers. The analyses revealed that one SNP (rs41266431) in GJA4 may be clinically relevant. Carriers homozygous for the G variant (n = 84; 73%) presented with worse LFTs (forced vital capacity (FVC) % predicted: mean 80/86.6, < 0.035) and a lower survival to ESLD ( < 0.029). For the TGBβ1 variant: 509 carriers of the C variant ( genotype, n = 105, 91.3%) had better LFTs (Forced expiratory flow at 75% of the FVC (FEF75% predicted: median 40/29.5, < 0.015), although a similar outcome to ESLD. A gene-gene interaction was not observed between TGBβ1 and GJA4 variants for any clinical measure. GJA4 variants are independent of TGBβ1 variants. Both variants had an impact on the LFTs, although only GJA4 variants were associated with an improved outcome for ESLD. The study was registered with ClinicalTrials.gov, number NCT04242420, retrospectively on January 24th, 2020.